{"schema_version":"secwatch.filing_event.v1","accession":"0001655759-23-000088","form_type":"8-K","ticker":"ARVN","cik":"0001655759","company_name":"ARVINAS, INC.","filed_at":"2023-11-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:29.959469+00:00","generated_at":"2026-06-08T15:50:33.406506+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Arvinas Q3 net loss $64M, cash $1B; vepdegestrant Phase 3 on track for 2H 2024","bullets":["Q3 2023 net loss $64.0M vs $66.2M prior year; revenue $34.6M from collaborations.","Cash, cash equivalents and marketable securities $1.004B as of Sept 30, 2023; runway into 2026.","VERITAC-2 Phase 3 trial of vepdegestrant in 2L+ ER+/HER2- breast cancer enrollment ongoing; top-line data 2H 2024.","Prioritized ARV-766 over bavdegalutamide for Phase 3 in mCRPC based on broader efficacy and superior tolerability.","Plan to submit two IND/CTA applications for BCL6 (oncology) and LRRK2 (neuroscience) PROTAC degraders by year-end 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001655759-23-000088","json":"https://secwatch.observer/filing/0001655759-23-000088.json","markdown":"https://secwatch.observer/filing/0001655759-23-000088.md","text":"https://secwatch.observer/filing/0001655759-23-000088.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1655759/000165575923000088/0001655759-23-000088-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1655759/000165575923000088/arvn-20231107.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T15:50:33.406506+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"aa8e1c9f37762bcac9ea1453d8d732959833ff9f","claim":"ARVINAS, INC. reported financial results for the third quarter ended September 30, 2023.","evidence_excerpt":"On November 7, 2023 , Arvinas, Inc. announced its financial results for the quarter ended September 30, 2023 and provided a corporate update.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1655759/000165575923000088/0001655759-23-000088-index.htm","confidence":0.7,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the third quarter ended September 30, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}